- About us
- Clinical trials
- News & Publications
SOTIO Establishes Strategic Advisory Board with world-renowned experts
SOTIO, a biotechnology company owned by the PPF Group, which develops innovative products for the treatment of cancer and autoimmune diseases, announced the creation of its Strategic Advisory Board today. SOTIO’s Advisory Board is comprised of internationally renowned experts in clinical research, translational medicine, business development and commercialization.
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
Dortmund, Germany and Prague, Czech Republic – The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.
Cellestia Biotech raises CHF 8 million seed financing from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage
Basel, Switzerland – January 26, 2017 – Cellestia Biotech AG, a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway, today announced the final closing of its seed financing rounds securing a total of CHF 8 million in funding. The total seed financing includes proceeds of CHF 0.5 million Seed A and CHF 2.3 million Seed B financing rounds conducted during 2016 and the proceeds of the final Seed C financing round closing at CHF 5.2 million today, in which PPF Group, as an institutional investor, and several private investors participated. The funds will enable Cellestia to advance the lead product CB-103 and to conduct and complete a first-in-man phase I clinical study. The preparations for launching the clinical program in 2017 are ongoing.